Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy

Hypertension

Volumn 55, Issue 5, 2010, Pages 1206-1209

  Vogt, Liffert ^a,b,c   Chiurchiu, Carlos ^c   Chadha Boreham, Harbajan ^d   Danaietash, Parisa ^d   Dingemanse, Jasper ^d   Hadjadj, Samy ^e   Krum, Henry ^f   Navis, Gerjan ^a   Neuhart, Eric ^d   Parvanova, Aneliya I ^c   Ruggenenti, Piero ^c   Woittiez, Arend Jan ^g   Zimlichman, Reuven ^h   Remuzzi, Giuseppe ^c   De Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Institute for Pharmacological Research Villa Camozzi   (Italy)

^d ACTELION PHARMACEUTICALS LTD   (Switzerland)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f MONASH UNIVERSITY   (Australia)

^g TWENTEBORG HOSPITAL   (Netherlands)

^h WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Albuminuria; Diabetic nephropathy; Hypertension; Palosuran; RAAS blockade; Urotensin antagonist

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; ENALAPRIL; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; NEUROPEPTIDE RECEPTOR; PALOSURAN; PERINDOPRIL; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; THIAZIDE DIURETIC AGENT; UROTENSIN; UROTENSIN RECEPTOR; VALSARTAN; VASOCONSTRICTOR AGENT;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CREATININE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLACEBOS; QUINOLINES; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM; UREA; UROTENSINS;

EID: 77951497845     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.149559     Document Type: Article

References (13)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;40:282-286. (Pubitemid 129515542)
2. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med. 2000; 10:229-237.
3. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens. 2001;19: 2185-2190. (Pubitemid 33135240)
4. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H, Murakami O. Role of urotensin II in patients on dialysis. Lancet. 2001;358:810-811. (Pubitemid 32868735)
5. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci. 2003;104:1-5. (Pubitemid 36249917)
6. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Müller C, Müller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF, Ziltener P. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4- hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiolog-ical role of the urotensin system. J Pharmacol Exp Ther. 2004;311: 204-212. (Pubitemid 39302621)
7. Clozel M, Hess P, Qiu C, Ding SS, Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther. 2006;316:1115-1121. (Pubitemid 43345285)
8. Sidharta PN, van Giersbergen PLM, Dingemanse J. Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy human subjects. J Clin Pharmacol. 2009;49:1168-1175.
9. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krä-henbühl S, Chadha-Boreham H, Dingemanse J. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther. 2006;80: 246-256. (Pubitemid 44313907)
10. Perico N, Benigni A, Zoja C, Delaini F, Remuzzi G. Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclo-sporin A. Am J Physiol. 1986;251:581-587. (Pubitemid 17176448)
11. Chau NP, Bouhanick B, Mestivier D, Taki M, Marre M. Normal and abnormal day-to-day variability of urinary albumin excretion in control and diabetic subjects. Diabetes Metab. 2000;26:36-41. (Pubitemid 30146091)
12. Zandi-Nejad K, Eddy AA, Glassock RJ, Brenner BM. Why is proteinuria an ominous biomarker of progressive kidney diease? Kidney Int. 2004; 92(suppl):S76-S89. (Pubitemid 43361438)
13. Perico N, Benigni A, Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nature Reviews. 2007;7:936-953.